Navigation Links
Research: Chemoresponse assay helps boost ovarian cancer survival
Date:4/25/2013

This spring, a team of researchers has released results from an eight-year study that shows improved survival rates for women diagnosed with ovarian cancer who undergo cancer tumor testing to determine the best treatment.

Part of the team was Richard G. Moore, MD, director of the Center for Biomarkers and Emerging Technologies and a gynecologic oncologist with the Program in Women's Oncology at Women & Infants Hospital of Rhode Island.

"Essentially, we have demonstrated that by using a tissue sample from the patient's tumor and a chemoresponse assay, we are able to determine which treatment may or may not work for her," Dr. Moore explains of the study, which was presented at a recent meeting of the Society of Gynecologic Oncology and in the trade publication Cure.

"This study shows that a woman with recurrent ovarian cancer could benefit from having a biopsy and chemosensitivity testing. The results from such testing will allow for the identification of chemotherapeutics that are active against the patient's disease and those that are not resulting in decreased toxicity from ineffective treatments. Learning that personal directed therapies may improve overall survival for these patients made this the first study in two decades to show a significant increase in survival in recurrent ovarian cancer."

The study, launched in 2004, included 283 women. Of those, 262 had successful biopsies which were tested in vitro, or in a test tube. The assay ChemoFx, by Precision Therapeutics, tested up to 15 approved treatment regimens on the samples, identifying chemotherapy drugs and regimens to which each tumor might be sensitive. The study was non-interventional, meaning that physicians chose the treatment regimens without knowing of the assay results. The researchers then evaluated the assay's result against actual patient outcomes.

"The assay identified at least one treatment to which the tumor would be sensitive in 52% of patients in the study," Dr. Moore says. "Overall, median survival was 37.5 months for patients with treatment-sensitive tumors, compared to 23.9 months for intermediate and resistant tumors."

Assay-directed therapy has long been debated among oncologists, he continues. Such debate provided the impetus for this study.


'/>"/>

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Women & Infants Hospital
Source:Eurekalert

Related medicine news :

1. Breast stem-cell research: Receptor teamwork is required and a new pathway may be involved
2. BioMed Central presents Challenges in Malaria Research: Progress Towards Elimination
3. Research: NCAA football exploits players in invisible labor market
4. Kinsey research: Postpartum women less stressed by threats unrelated to the baby
5. Research: Lupus drugs carry no significant cancer risk for patients
6. Research: Military women may have higher risk for STIs
7. Gut microbiota research: Pinpointing a moving target
8. Research: Brain cant cope with making a left-hand turn and talking on hands-free cell phone
9. UTHealth research: Low incidence of venous insufficiency in MS
10. Multiple sclerosis research: The thalamus moves into the spotlight
11. Research: Women over 40 still need effective contraception
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital ... area economy by obtaining investment capital for emerging technology companies. SCP has ... have already resulted in more than a million dollars of capital investment for ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Venture ... Golf Classic Tournament held on June 20th at the Woodmont Country Club at ... Luke’s Wings, an organization dedicated to helping service members that have been wounded in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Advanced Plastic Surgery Institute ... pageant as its official Medspa Sponsor. Dr. Josh Olson, a board-certified plastic surgeon, ... , Dr. Olson says the decision to support the pageant in an official ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology ... outcomes platform, Bracket eCOA (SM) 6.0, at the 52 ... 30, 2016 in Philadelphia , Pennsylvania.  A ... product of its kind to fully integrate with RTSM, will ... 6.0 is a flexible platform for electronic clinical outcomes assessments ...
Breaking Medicine Technology: